Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) announced that it has amended its BELVIQ (lorcaserin HCl) marketing and supply agreement with Eisai Co.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) and Eisai Inc.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) announced that it has completed enrollment in the ralinepag phase 2 trial.
In a research report issued Tuesday, Needham analyst Alan Carr reiterated a Hold rating on Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), after the drug maker reported third-quarter results and …
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) reported financial results for the third quarter endedSeptember 30, 2016, and provided a corporate update.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) announced that Dr.
Eisai Inc. and Arena Pharmaceuticals, Inc.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) announced the formation of Beacon Discovery Inc.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) released second-quarter results and hosted a quarterly call, where management provided a corporate update as well as an update on clinical …
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) reported financial results for the second quarter ended June 30, 2016, and provided a corporate update.
